FDA
-
-
-
-
-
-
-
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
-
-
-
-
-
-
-
Forma Therapeutics Holdings (FMTX) Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease
-
-
251,895 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All